BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...
BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...
Palantir reported fourth-quarter revenue of $827.52 million, beating the consensus estimate of $775.91 million. The company reported fourth-quarter adjusted earnings of 14 cents per share, beating ...